{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:55Z","timestamp":1787181955345,"version":"build-2736575974"},"reference-count":100,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antiviral drugs are pivotal in the prevention and management of infections caused\n                    by viruses, ranging from common cold viruses to life-threatening pathogens like\n                    human immunodeficiency virus, hepatitis viruses, Ebola virus, etc. Furthermore,\n                    antiviral therapy is increasingly being integrated into the management of\n                    chronic viral infections to restrain their replication, avert disease\n                    progression, and minimize the risk of complications. The availability of newer\n                    generations of antiviral drugs, particularly direct-acting antivirals, and\n                    combination therapies have significantly improved treatment outcomes, offering\n                    better cure speed, shorter treatment time, and reduced side effects as compared\n                    to older-generation antivirals. This comprehensive review provides an in-depth\n                    analysis of the diverse classes of antiviral drugs, their mechanisms of action,\n                    clinical applications, challenges, and future directions. With a focus on recent\n                    advancements and emerging trends, the current landscape of antiviral drug\n                    development and its implications for global public health are also\n                    discussed.<\/jats:p>","DOI":"10.1055\/a-2929-1881","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:10:56Z","timestamp":1787181056000},"source":"Crossref","is-referenced-by-count":0,"title":["A Review of the Current Status of Antiviral Drugs Targeting Human\n                    Immunodeficiency Virus, Hepatitis and Others"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-1649","authenticated-orcid":false,"given":"Abid","family":"Qureshi","sequence":"additional","affiliation":[{"name":"University of Kashmir, J&K, India","place":["Srinagar"],"department":["Biotechnology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehtishamul","family":"Haq","sequence":"additional","affiliation":[{"name":"University of Kashmir, J&K, India","place":["Srinagar"],"department":["Biotechnology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1089\/vbz.2020.2661","article-title":"A review on emerging infectious diseases prioritized under the 2018 WHO research\n                    and development blueprint: Lessons from the Indian context","volume":"21","author":"L P Kojom","year":"2021","journal-title":"Vector Borne Zoonotic Dis"},{"key":"ref2","first-page":"35","article-title":"A review: Mechanism of action of antiviral\n                    drugs","author":"S Kausar","year":"2021","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijbiomac.2021.01.076","article-title":"Trends and strategies to combat viral infections: A review on FDA approved\n                    antiviral drugs","volume":"172","author":"D R Tompa","year":"2021","journal-title":"Int J Biol Macromol"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/v13040667","article-title":"Broad-spectrum antiviral strategies and nucleoside analogues","volume":"13","author":"R J Geraghty","year":"2021","journal-title":"Viruses"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults:\n                    2022 recommendations of the international antiviral society-USA panel","volume":"329","author":"R T Gandhi","year":"2023","journal-title":"JAMA"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","article-title":"Update and latest advances in antiretroviral therapy","volume":"43","author":"L Menendez-Arias","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"ref7","volume-title":"Highly Active Antiretroviral Therapy (HAART)","author":"J S Eggleton","year":"2024"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.idc.2024.06.001","article-title":"Advancing toward a human immunodeficiency virus cure: Initial progress on a\n                    difficult path","volume":"38","author":"D M Margolis","year":"2024","journal-title":"Infect Dis Clin North Am"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/v14061325","article-title":"Direct-acting antiviral agents for hepatitis C virus infection-from drug\n                    discovery to successful implementation in clinical practice","volume":"14","author":"C Dietz","year":"2022","journal-title":"Viruses"},{"issue":"13","key":"ref10","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1080\/14656566.2021.1921737","article-title":"An update on direct antiviral agents for the treatment of hepatitis C","volume":"22","author":"C Stanciu","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"06","key":"ref11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cld.978","article-title":"Hepatitis C virus elimination by 2030: Conquering mount improbable","volume":"16","author":"R K Dhiman","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"04","key":"ref12","first-page":"105797","article-title":"Drug development for chronic hepatitis B functional cure: Recent progress","volume":"17","author":"T Liu","year":"2025","journal-title":"World J Hepatol"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2468-1253(25)00053-6","article-title":"Scientific and medical evidence informing expansion of hepatitis B treatment\n                    guidelines","volume":"10","author":"P T Kennedy","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"24","key":"ref14","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.2174\/0929867325666180309105519","article-title":"Acyclovir in the treatment of herpes viruses\u2014a review","volume":"27","author":"K Klysik","year":"2020","journal-title":"Curr Med Chem"},{"issue":"07","key":"ref15","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1128\/AAC.46.7.2238-2243.2002","article-title":"Acyclovir cream for treatment of herpes simplex labialis: Results of two\n                    randomized, double-blind, vehicle-controlled, multicenter clinical trials","volume":"46","author":"S L Spruance","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/QCO.0000000000000498","article-title":"Neuraminidase inhibitor resistance in influenza: A clinical perspective","volume":"31","author":"N Lee","year":"2018","journal-title":"Curr Opin Infect Dis"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14656566.3.2.103","article-title":"Neuraminidase inhibitors for the treatment and prevention of influenza","volume":"3","author":"J L McKimm-Breschkin","year":"2002","journal-title":"Expert Opin Pharmacother"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/cid\/ciad685","article-title":"Review: The landscape of antiviral therapy for COVID-19 in the era of widespread\n                    population immunity and omicron-lineage viruses","volume":"78","author":"E A Meyerowitz","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12985-023-02269-8","article-title":"Optimizing COVID-19 treatment in immunocompromised patients: Early combination\n                    therapy with remdesivir, nirmatrelvir\/ritonavir and sotrovimab","volume":"20","author":"I Gentile","year":"2023","journal-title":"Virol J"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.antiviral.2018.04.004","article-title":"The evolution of nucleoside analogue antivirals: A review for chemists and\n                    non-chemists. Part 1: Early structural modifications to the nucleoside\n                    scaffold","volume":"154","author":"K L Seley-Radtke","year":"2018","journal-title":"Antiviral Res"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer\n                    and viral diseases","volume":"12","author":"L P Jordheim","year":"2013","journal-title":"Nat Rev Drug Discovery"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"114136","DOI":"10.1016\/j.ejmech.2022.114136","article-title":"Non-nucleoside structured compounds with antiviral activity-past 10 years\n                    (2010-2020)","volume":"231","author":"M Denel-Bobrowska","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery,\n                    development, and use in the treatment of HIV-1 infection: A review of the last\n                    20 years (1989\u20132009)","volume":"85","author":"M P de Bethune","year":"2010","journal-title":"Antiviral Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/bs.enz.2021.07.001","article-title":"Mechanisms of inhibition of viral RNA replication by nucleotide analogs","volume":"49","author":"K A Johnson","year":"2021","journal-title":"Enzymes"},{"key":"ref25","first-page":"19","article-title":"A review and clinical understanding of tenofovir: Tenofovir\n                    disoproxil fumarate versus tenofovir alafenamide","author":"C Wassner","year":"2020","journal-title":"J Int Assoc\n                    Provid AIDS Care"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/v16030366","article-title":"Recent advances on targeting proteases for antiviral development","volume":"16","author":"PH O Borges","year":"2024","journal-title":"Viruses"},{"issue":"09","key":"ref27","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17425247.2022.2121817","article-title":"Recent advances in nanoformulation development of Ritonavir, a key protease\n                    inhibitor used in the treatment of HIV-AIDS","volume":"19","year":"2022","journal-title":"Expert Opin Drug Deliv"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2165\/00003495-200060060-00009","article-title":"Lopinavir","volume":"60","author":"M Hurst","year":"2000","journal-title":"Drugs"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"8255","DOI":"10.3390\/cimb45100521","article-title":"A synopsis of hepatitis C virus treatments and future perspectives","volume":"45","author":"C Medina","year":"2023","journal-title":"Curr Issues Mol Biol"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cld.2009.05.008","article-title":"Boceprevir, an NS3 protease inhibitor of HCV","volume":"13","author":"K Berman","year":"2009","journal-title":"Clin Liver Dis"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/v13050735","article-title":"HIV-1 entry and membrane fusion inhibitors","volume":"13","author":"T Xiao","year":"2021","journal-title":"Viruses"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1517\/13543784.11.12.1837","article-title":"Enfuvirtide","volume":"11","author":"R Y Chen","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"issue":"16","key":"ref33","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","article-title":"HIV-1 integrase inhibitors: A comparative review of efficacy and safety","volume":"80","author":"K K Scarsi","year":"2020","journal-title":"Drugs"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00003495-200868010-00009","article-title":"Raltegravir","volume":"68","author":"J D Croxtall","year":"2008","journal-title":"Drugs"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/13543784.2012.658914","article-title":"Elvitegravir: A once-daily inhibitor of HIV-1 integrase","volume":"21","author":"T Wills","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.2147\/DDDT.S84850","article-title":"Dolutegravir\u2014a review of the pharmacology, efficacy, and safety in the treatment\n                    of HIV","volume":"9","author":"C E Kandel","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.cytogfr.2005.05.009","article-title":"HIV chemokine receptor inhibitors as novel anti-HIV drugs","volume":"16","author":"K Princen","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref38","first-page":"5447","article-title":"Maraviroc: A review of its use in HIV infection and beyond","volume":"9","author":"S M Woollard","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"03","key":"ref39","first-page":"210","article-title":"Chemokines and chemokine receptors in HIV infection: Role in pathogenesis and\n                    therapeutics","volume":"52","author":"P Suresh","year":"2006","journal-title":"J Postgrad Med"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/BF02014325","article-title":"Antiherpes drugs: Promises and pitfalls","volume":"3","author":"E de Clercq","year":"1984","journal-title":"Eur J Clin Microbiol"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4103\/ijp.IJP_555_18","article-title":"Efficacy of valacyclovir and famciclovir in herpes zoster: A comparative\n                    study","volume":"52","author":"A Bist","year":"2020","journal-title":"Indian J Pharmacol"},{"issue":"02","key":"ref42","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3390\/v14020434","article-title":"Current trend in antiviral therapy for chronic hepatitis B","volume":"14","author":"R N Chien","year":"2022","journal-title":"Viruses"},{"issue":"02","key":"ref43","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cgh.2021.04.045","article-title":"Tenofovir alafenamide for drug-resistant hepatitis B: A randomized trial for\n                    switching from tenofovir disoproxil fumarate","volume":"20","author":"K S Byun","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"04","key":"ref44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12664-018-0878-1","article-title":"Pegylated interferon-based sequential therapy for treatment of HBeAg reactive\n                    pediatric chronic hepatitis B-First study in children","volume":"37","author":"B B Lal","year":"2018","journal-title":"Indian J Gastroenterol"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S2468-1253(23)00335-7","article-title":"Direct-acting antiviral therapies for hepatitis C infection: Global\n                    registration, reimbursement, and restrictions","volume":"9","author":"A D Marshall","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.apsb.2015.09.008","article-title":"Direct anti-HCV agents","volume":"6","author":"X Zhang","year":"2016","journal-title":"Acta Pharm Sin B"},{"issue":"09","key":"ref47","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/jvh.13305","article-title":"Real-world effectiveness of glecaprevir\/pibrentasvir and ledipasvir\/sofosbuvir\n                    for mixed genotype hepatitis C infection: A multicenter pooled analysis in\n                    Taiwan","volume":"27","author":"W N Chiu","year":"2020","journal-title":"J Viral Hepat"},{"issue":"02","key":"ref48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.17998\/jlc.2022.05.24","article-title":"Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular\n                    carcinoma recurrence and death after curative treatment","volume":"22","author":"Y H Ahn","year":"2022","journal-title":"J Liver Cancer"},{"issue":"22","key":"ref49","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.3390\/cells11223531","article-title":"Treatment of chronic hepatitis D with bulevirtide-a fight against two foes-an\n                    update","volume":"11","author":"P Ferenci","year":"2022","journal-title":"Cells"},{"issue":"04","key":"ref50","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jhep.2024.05.001","article-title":"Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety\n                    results through week 96 from a phase III randomized trial","volume":"81","author":"H Wedemeyer","year":"2024","journal-title":"J Hepatol"},{"issue":"24","key":"ref51","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1001\/jama.2023.23242","article-title":"Hepatitis D: A review","volume":"330","author":"F Negro","year":"2023","journal-title":"JAMA"},{"issue":"01","key":"ref52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.livres.2024.01.001","article-title":"Viral hepatitis E: Clinical manifestations, treatment, and prevention","volume":"8","author":"Q Luo","year":"2024","journal-title":"Liver Res"},{"issue":"03","key":"ref53","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jinf.2022.06.005","article-title":"High efficacy of glecaprevir\/pibrentasvir for HCV-infected individuals with\n                    active drug use","volume":"85","author":"A Gonzalez-Serna","year":"2022","journal-title":"J Infect"},{"issue":"03","key":"ref54","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1060028013513558","article-title":"Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1\n                    infection","volume":"48","author":"R C Rathbun","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"02","key":"ref55","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jinf.2022.10.040","article-title":"Molnupiravir for SARS-CoV-2 infection: Public health and policy\n                    implications","volume":"86","author":"E J Gray","year":"2023","journal-title":"J Infect"},{"issue":"08","key":"ref56","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2146\/ajhp080206","article-title":"Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection","volume":"66","author":"R Yost","year":"2009","journal-title":"Am J Health Syst Pharm"},{"issue":"06","key":"ref57","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-015-0381-2","article-title":"Ledipasvir\/Sofosbuvir: A review of its use in chronic hepatitis C","volume":"75","author":"G M Keating","year":"2015","journal-title":"Drugs"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"e01741","DOI":"10.1016\/j.idcr.2023.e01741","article-title":"Ledipasvir\/sofosbuvir and ribavirin for the treatment of ribavirin-refractory\n                    persistent hepatitis E virus infection","volume":"32","author":"J Gallacher","year":"2023","journal-title":"IDCases"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"104677","DOI":"10.1016\/j.compbiomed.2021.104677","article-title":"Computational identification of repurposed drugs against viruses causing\n                    epidemics and pandemics via drug-target network analysis","volume":"136","author":"A Rajput","year":"2021","journal-title":"Comput Biol Med"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"117963","DOI":"10.1016\/j.lfs.2020.117963","article-title":"Virtual screening, ADME\/Tox predictions and the drug repurposing concept for\n                    future use of old drugs against the COVID-19","volume":"256","author":"L Hage-Melim","year":"2020","journal-title":"Life Sci"},{"issue":"01","key":"ref61","doi-asserted-by":"crossref","first-page":"14570","DOI":"10.1038\/s41598-023-41820-z","article-title":"A multi-targeted computational drug discovery approach for repurposing\n                    tetracyclines against monkeypox virus","volume":"13","author":"T A Alandijany","year":"2023","journal-title":"Sci Rep"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cbdd.12834","article-title":"AVCpred: An integrated web server for prediction and design of antiviral\n                    compounds","volume":"89","author":"A Qureshi","year":"2017","journal-title":"Chem Biol Drug Des"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13321-018-0266-y","article-title":"HIVprotI: An integrated web based platform for prediction and design of HIV\n                    proteins inhibitors","volume":"10","author":"A Qureshi","year":"2018","journal-title":"J Cheminform"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"110239","DOI":"10.1016\/j.virol.2024.110239","article-title":"Evolution of drug resistance against antiviral agents that target cellular\n                    factors","volume":"600","author":"N Kumar","year":"2024","journal-title":"Virology"},{"issue":"04","key":"ref65","first-page":"559","article-title":"2022 update of the drug resistance mutations in HIV-1","volume":"30","author":"A M Wensing","year":"2022","journal-title":"Top Antivir Med"},{"issue":"04","key":"ref66","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.tibtech.2019.09.009","article-title":"Next-Generation Sequencing: An eye-opener for the surveillance of antiviral\n                    resistance in influenza","volume":"38","author":"LA E Van Poelvoorde","year":"2020","journal-title":"Trends Biotechnol"},{"issue":"08","key":"ref67","first-page":"e9536","article-title":"Neuropsychiatric effects of antiviral drugs","volume":"12","author":"N Zareifopoulos","year":"2020","journal-title":"Cureus"},{"issue":"03","key":"ref68","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.iac.2014.04.011","article-title":"Antiviral drug allergy","volume":"34","author":"B Milpied-Homsi","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"103051","DOI":"10.1016\/j.healthplace.2023.103051","article-title":"Global inequities in access to COVID-19 health products and technologies: A\n                    political economy analysis","volume":"83","author":"D Gleeson","year":"2023","journal-title":"Health Place"},{"issue":"03","key":"ref70","doi-asserted-by":"crossref","first-page":"e220050","DOI":"10.1001\/jamahealthforum.2022.0050","article-title":"Strategies to promote equity in COVID-19 antiviral\n                    treatment","volume":"3","author":"K Fiscella","year":"2022","journal-title":"JAMA Health Forum"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/B978-0-323-91814-5.00021-0","volume-title":"Chapter 29\u2014Clinical Trials and Regulatory considerations of Antiviral agents, in\n                    Viral Infections and Antiviral Therapies","author":"S Bhargava","year":"2023"},{"issue":"06","key":"ref72","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s43440-022-00388-7","article-title":"Oral antiviral treatments for COVID-19: Opportunities and challenges","volume":"74","author":"L Rahmah","year":"2022","journal-title":"Pharmacol Rep"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev-pharmtox-010716-104533","article-title":"Accelerating drug development: Antiviral therapies for emerging viruses as a\n                    model","volume":"57","author":"M Everts","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"07","key":"ref74","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3390\/biomedicines11071944","article-title":"Development of therapy based on the exploration of biological events underlying\n                    the pathogenetic mechanisms of chronic hepatitis B infection","volume":"11","author":"SM F Akbar","year":"2023","journal-title":"Biomedicines"},{"key":"ref75","first-page":"139","volume-title":"Antiviral drug discovery in emerging economics: Challenges and\n                    opportunities","author":"A Navabhatra","year":"2025"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1013285","DOI":"10.3389\/fddsv.2022.1013285","article-title":"Artificial intelligence for antiviral drug\n                    discovery in low resourced settings: A perspective","volume":"2","author":"C T Namba-Nzanguim","year":"2022","journal-title":"Frontiers\n                    in Drug Discovery"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1101\/2024.06.02.596989","article-title":"Persistent neurological deficits in mouse PASC reveal antiviral drug\n                    limitations","author":"A K Verma","year":"2024"},{"issue":"02","key":"ref78","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2174\/1570180819666220928151734","article-title":"Learning from the in vitro biological activity data of current antiviral\n                    medicines for the successful development of new antiviral drug candidates","volume":"21","author":"F Murilo Barboza","year":"2024","journal-title":"Lett Drug Des Discovery"},{"issue":"01","key":"ref79","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s43141-022-00353-0","article-title":"A review on drug repurposing in COVID-19: From antiviral drugs to herbal\n                    alternatives","volume":"20","author":"A Sezer","year":"2022","journal-title":"J Genet Eng Biotechnol"},{"issue":"05","key":"ref80","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/bfgp\/elad058","article-title":"Computational drug repurposing for viral infectious diseases: A case study on\n                    monkeypox","volume":"23","author":"S Saha","year":"2024","journal-title":"Brief Funct Genomics"},{"issue":"04","key":"ref81","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/imm.12246","article-title":"Minocycline attenuates HIV-1 infection and suppresses chronic immune activation\n                    in humanized NOD\/LtsZ-scidIL-2Rgamma(null) mice","volume":"142","author":"M Singh","year":"2014","journal-title":"Immunology"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"1339338","DOI":"10.3389\/fimmu.2024.1339338","article-title":"Effects of statins beyond lipid-lowering agents in ART-treated\n                    HIV infection","volume":"15","author":"V Mehraj","year":"2024","journal-title":"Front Immunol"},{"issue":"01","key":"ref83","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12985-018-1050-3","article-title":"Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for\n                    HBV\/HIV coinfection: A meta-analysis","volume":"15","author":"A Luo","year":"2018","journal-title":"Virol J"},{"issue":"15","key":"ref84","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.2174\/0929867327666200812215852","article-title":"Drug repurposing: A strategy for discovering inhibitors against emerging viral\n                    infections","volume":"28","author":"I J Dos Santos Nascimento","year":"2021","journal-title":"Curr Med Chem"},{"key":"ref85","first-page":"01","article-title":"Remdesivir for the treatment of\n                    COVID-19","volume":"1","author":"F Grundeis","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"09","key":"ref86","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1007\/s12325-022-02256-5","article-title":"Ribavirin for treatment of subjects with respiratory syncytial virus-related\n                    infection: A systematic review and meta-analysis","volume":"39","author":"S Tejada","year":"2022","journal-title":"Adv Ther"},{"issue":"04","key":"ref87","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"C E Samuel","year":"2001","journal-title":"Clin Microbiol Rev"},{"issue":"01","key":"ref88","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.it.2020.11.003","article-title":"B. Canard, and A. Trautmann, combining antivirals and immunomodulators to fight\n                    COVID-19","volume":"42","author":"V Feuillet","year":"2021","journal-title":"Trends Immunol"},{"issue":"01","key":"ref89","doi-asserted-by":"crossref","first-page":"e00698","DOI":"10.1002\/prp2.698","article-title":"Targeting host cell proteases as a potential treatment strategy to limit the\n                    spread of SARS-CoV-2 in the respiratory tract","volume":"9","author":"I A El-Shimy","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"ref90","first-page":"8","article-title":"Targeting viral entry as a strategy for broad-spectrum antivirals","author":"M Mazzon","year":"2019","journal-title":"F1000Res"},{"issue":"01","key":"ref91","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1080\/22221751.2022.2071175","article-title":"Virus-host interaction networks as new antiviral drug targets for IAV and\n                    SARS-CoV-2","volume":"11","author":"N Chen","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jconrel.2021.01.017","article-title":"Development of nanoparticle-delivery systems for antiviral agents: A review","volume":"331","author":"R Delshadi","year":"2021","journal-title":"J Control Release"},{"issue":"05","key":"ref93","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.3390\/pharmaceutics15051538","article-title":"Uses and challenges of antiviral polyclonal and monoclonal antibody\n                    therapies","volume":"15","author":"E B Struble","year":"2023","journal-title":"Pharmaceutics"},{"issue":"11","key":"ref94","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3390\/v15112180","article-title":"Vaccination and antiviral treatment reduce the time to negative SARS-CoV-2 Swab:\n                    A real-life study","volume":"15","author":"A De Vito","year":"2023","journal-title":"Viruses"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1016\/j.csbj.2021.05.037","article-title":"Prediction of repurposed drugs for Coronaviruses using artificial intelligence\n                    and machine learning","volume":"19","author":"A Rajput","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"issue":"02","key":"ref96","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/bib\/bbaa421","article-title":"DrugRepV: A compendium of repurposed drugs and chemicals targeting epidemic and\n                    pandemic viruses","volume":"22","author":"A Rajput","year":"2021","journal-title":"Brief Bioinform"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.3389\/fmicb.2018.03121","article-title":"Anti-flavi: A web platform to predict inhibitors of flaviviruses using QSAR and\n                    peptidomimetic approaches","volume":"9","author":"A Rajput","year":"2018","journal-title":"Front Microbiol"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.csbj.2022.06.060","article-title":"Targeting non-structural proteins of Hepatitis C virus for predicting repurposed\n                    drugs using QSAR and machine learning approaches","volume":"20","author":"S Kamboj","year":"2022","journal-title":"Comput Struct Biotechnol J"},{"issue":"03","key":"ref99","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s11030-021-10291-7","article-title":"Anti-Ebola: An initiative to predict Ebola virus inhibitors through machine\n                    learning","volume":"26","author":"A Rajput","year":"2022","journal-title":"Mol Divers"},{"issue":"01","key":"ref100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/v16010045","article-title":"Anti-dengue: A machine learning-assisted prediction of small molecule antivirals\n                    against dengue virus and implications in drug repurposing","volume":"16","author":"S Gautam","year":"2023","journal-title":"Viruses"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2929-1881.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:11:07Z","timestamp":1787181067000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2929-1881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":100,"URL":"https:\/\/doi.org\/10.1055\/a-2929-1881","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}